Acaya (Acalabrutinib 100 mg) is a targeted oral therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Zydus |
| Packing | 60 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acalnib Acalabrutinib 100 mg Capsules are an oral targeted therapy used for the treatment of certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Hetero |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acabrunat Acalabrutinib 100 mg Capsules are an oral targeted therapy used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Natco |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acaone Acalabrutinib 100 mg Capsules are an oral targeted therapy used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Acalabrutinib works by blocking the Bruton’s tyrosine kinase (BTK) enzyme, which helps prevent the growth and spread of cancer cells, thereby slowing disease progression and improving treatment outcomes.
| Composition | Acalabrutinib |
| Manufacturer | MSN |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
